Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, ...

Biogen is addressing profitability concerns and a lack of top-line growth. Read more to see an overview and analysis of BIIB ...

Biogen's Alzheimer therapy, Leqembi, is gaining traction with Q1'24 sales of $19m, nearly tripling Q4 revenues. Read my ...

The FDA will hold a "listening session" on June 13 to hear what the public thinks about its advisory committees. Comprised of ...

Q1 2024 Earnings Call April 25, 2024 Sage Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.8 EPS, ...

Viehbacher's pay that year was exceeded only by Jason Robins, the CEO of DraftKings, and Douglas Ingram, president and chief ...

At an annual meeting of the USA-India Chamber of Commerce in Boston, Shanghvi told a gathering of leading multinational drug ...

In the preceding three months, 27 analysts have released ratings for Biogen (NASDAQ:BIIB), presenting a wide array of ...

A Boston company got FDA approval for its first drug, called mavorixafor, the first-ever treatment for a rare disease that ...

Annovis Bio heralded a “significantly higher rate of improvement” in patients with Alzheimer’s disease who received ...

We can also look at clobbered shares of Biogen (NASDAQ:BIIB) – another one of the top retirement stocks at 52-week lows to ...

Prologis, Inc. (NYSE:PLD) is one of the most promising stocks to buy before they take off. Other such stocks include Li Auto ...